Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSH	ΙP
--	----

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Boral Anthony L.						2. Issuer Name and Ticker or Trading Symbol Blueprint Medicines Corp [BPMC]								heck a	all applic Directo	,			wner
(Last) (First) (Middle) C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET						3. Date of Earliest Transaction (Month/Day/Year) 12/17/2019								X	below)				рсспу
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)				_ 4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individ ne) X						
(=:5)		•		n-Deriv	vativ	e Se	curit	ies Ac	auired	. Dis	sposed o	f. or Be	neficia	llv O	wned				
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transact Date (Month/Day)				action	2/ Ex	A. Deemed kecution Date, any lonth/Day/Year)		3.		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			5. Amou Securition Benefici Owned I		nt of es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Price	- 1	Reported Transact (Instr. 3 a	tion(s)			(Instr. 4)	
Common Stock 12/17/2					7/2019	.019			M ⁽¹⁾		10,000	A \$8		В	10,000			D	
Common Stock 12/17/2					7/2019	2019			S ⁽¹⁾		6,070	D	\$76.8	7(2)	3,9	930		D	
Common Stock 12/17/2					7/2019	2019			S ⁽¹⁾		3,930	D	\$76.1	1(3)	(3) 0		D		
		-	Table II -								osed of, convertil			y Ov	vned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	ed n Date,	4. Transa Code (8)	ection	5. Number of		6. Date Exercis Expiration Dat (Month/Day/Ye		sable and	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		Der Sec	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Own Form Director In (I) (In	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to	otion \$8.8 12/17/2019			M ⁽¹⁾			10,000	(4)		02/10/2025	Common Stock	10,000		\$0	3,030		D		

Explanation of Responses:

- 1. Effected pursuant to a trading plan adopted on April 3, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- 2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$76.52 to \$77.40 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.
- 3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$75.52 to \$76.51 per share.
- 4. This option was granted on February 10, 2015. This option vested with respect to 25% of the shares underlying the option on February 9, 2016 and as to an additional 1/48th of the shares underlying the option each month thereafter.

/s/ Christopher Frankenfield, Attorney-in-Fact 12/19/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.